Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 29;14(17):4189.
doi: 10.3390/cancers14174189.

Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data?

Claudia Mosillo  1 , Maria Letizia Calandrella  1 , Claudia Caserta  1 , Serena Macrini  1 , Annalisa Guida  1 , Grazia Sirgiovanni  1 , Sergio Bracarda  1
Affiliations
Review

Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data?

Claudia Mosillo et al. Cancers (Basel). .

Abstract

Prostate cancer is the second most common diagnosed cancer and the fifth leading cause of cancer-related deaths in men worldwide. Despite significant advances in the management of castration-sensitive prostate cancer, the majority of patients develop a castration-resistant disease after a median duration of treatment of 18-48 months. The transition to a castrate resistance state could rely on alternative survival pathways, some related to androgen-independent mechanisms. Although several agents have been approved in this setting, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease. Recent studies revealed some of the complex pathways underlying inherited and acquired mechanisms of resistance to available treatments. A better understanding of these pathways may lead to significant improvements in survival by providing innovative therapeutic targets. The present comprehensive review attempts to provide an overview of recent progress in novel targeted therapies and near-future directions.

Keywords: DDR; MSI; PTEN; dMMR; mCRPC; precision medicine; prostate cancer; target therapy.

PubMed Disclaimer

Conflict of interest statement

S.B.: Advisory Board or Steering Committee Member (uncompensated) for Bayer, Janssen, Astellas, Pfizer, BMS, Roche-Genentech, Ipsen, MSD, AAA, Sanofi-Genzyme, Merck, AstraZeneca. The rest of the authors declare no conflict of interest.

References

    1. Culp M.B., Soerjomataram I., Efstathiou J.A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur. Urol. 2020;77:38–52. doi: 10.1016/j.eururo.2019.08.005. - DOI - PubMed
    1. Sweeney C.J., Chen Y., Carducci M. Chemohormonal therapy in metastatic hormonesensitive prostate cancer. N. Engl. J. Med. 2015;373:737–746. doi: 10.1056/NEJMoa1503747. - DOI - PMC - PubMed
    1. Fizazi K., Tran N., Fein L. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686–700. doi: 10.1016/S1470-2045(19)30082-8. - DOI - PubMed
    1. Chi K.N., Chowdhury S., Bjartell A. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J. Clin. Oncol. 2021;39:2294–2303. doi: 10.1200/JCO.20.03488. - DOI - PubMed
    1. Armstrong A.J., Szmulewitz R.Z., Petrylak D.P. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J. Clin. Oncol. 2019;37:2974–2986. doi: 10.1200/JCO.19.00799. - DOI - PMC - PubMed